Posters

Innovations in the treatment of retinovascular macular oedema: macular double block

Poster Details

First Author: M.Ismailov -0

Co Author(s):                  

Abstract Details

Purpose:

Increase the effectiveness of the treatment of macular edema in the early stages, before the development of pathological changes and permanent visual loss. Provide a high anatomic and functional results.

Setting:

Department of Ophthalmology with Postgraduate Course of Daghestan State Medical Academy, Eye Clinic High Technology, Makhachkala, Russia

Methods:

Patients were followed up for 1 year. All patients with macular edema, secondary to nonischemic Branch retinal vein occlusion were divided into two groups: the main group - 40 people (40 eyes) and a comparison group - 39 people (40 eyes). All patients of the main group were treated with a patented technique «macular double block», that consists of two consecutive stages of treatment. Initially were injected intravitreal ranibizumab (0.5 mg) after 30 minutes made micropulse subthreshold photocoagulation of the retina. In patients comparison group were injected intravitreal ranibizumab (0.5 mg) monthly for 3 months.

Results:

Best corrected visual acuity of patients of the main group increased by one or more lines in 90% (36 eyes) versus 77.5% (31 eyes) of the patients of comparison group. Macular thickness in the eyes of the main group was an average of 196 microns, in the eyes of the comparison group - 219 microns. For all the study patients of the main group showed no relative or absolute defects in the area of laser exposure in the mode of the micropulse modulation by the author's method.

Conclusions:

The developed technology of treatment allows to reach more complete recovery of the anatomy of the macula, in the early stages, and greater visual acuity in comparison with monotherapy by inhibitors of VEGF (ranibizumab), with equal safety and atraumatic profile. This technology of the treatment of retinovascular macular edema allows to reduce number intravitreal injections, compared with the intravitreal ranibizumab monotherapy. FINANCIAL DISCLOUSRE: NONE